HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: M500517-JLR200v1 47/5/1014    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carlson, C. S. Articles by Jarvik, G. P. Search for Related Content PubMed PubMed Citation Articles by Carlson, C. S. Articles by Jarvik, G. P.

Journal of Lipid Research, Vol. 47, 1014-1024, May 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology

TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease

Christopher S. Carlson^*, Patrick J. Heagerty, Thomas S. Hatsukami, Rebecca J. Richter^**, Jane Ranchalis^**, Julieann Lewis^**, Tamara J. Bacus^**, Laura A. McKinstry^**, Gerard D. Schellenberg, Mark Rieder^***, Deborah Nickerson^***, Clement E. Furlong^**,***, Alan Chait and Gail P. Jarvik^1,**,***

^* The Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, The University of Washington
Department of Biostatistics, Seattle, WA
Puget Sound Veterans Affairs Health Care System, Seattle, WA
^** Department of Medicine (Divisions of Medical Genetics), Seattle, WA
Department of Neurology, Seattle, WA
^*** Department of Genome Sciences, Seattle, WA
Department of Medicine (Metabolism, Endocrinology , and Nutrition), Seattle, WA

Published, JLR Papers in Press, February 11, 2006.

¹ To whom correspondence should be addressed. e-mail: pair{at}u.washington.edu

	ABSTRACT

TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
Paraoxonase 1 (PON1) activity is consistently predictive of vascular disease, although the genotype at four functional PON1 polymorphisms is not. To address this inconsistency, we investigated the role of all common PON1 genetic variability, as measured by tagging single-nucleotide polymorphisms (tagSNPs), in predicting PON1 activity for phenylacetate hydrolysis, LDL susceptibility to oxidation ex vivo, plasma homocysteine (Hcy) levels, and carotid artery disease (CAAD) status. The biological goal was to establish whether additional common genetic variation beyond consideration of the four known functional SNPs improves prediction of these phenotypes. PON2 and PON3 tagSNPs were secondarily evaluated. Expanded analysis of an additional 26 tagSNPs found evidence of previously undescribed common PON1 polymorphisms that affect PON1 activity independently of the four known functional SNPs. PON1 activity was not significantly correlated with LDL oxidative susceptibility, but genotypes at the PON1_-108 promoter polymorphism and several other PON1 SNPs were. Neither PON1 activity nor PON1 genotype was significantly correlated with plasma Hcy levels. This study revealed previously undetected common functional PON1 polymorphisms that explain 4% of PON1 activity and a high rate of recombination in PON1, but the sum of the common PON1 locus variation does not explain the relationship between PON1 activity and CAAD.

Supplementary key words paraoxonase • carotid artery disease • LDL oxidation • haplotype • genotype • tagging single-nucleotide polymorphism

Abbreviations: AIC, Akaike's Information Criterion; CAAD, carotid artery disease; CVD, cardiovascular disease; Hcy, homocysteine; PON, paraoxonase; tagSNP, tagging single-nucleotide polymorphism

	INTRODUCTION

TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
Paraoxonase 1 (PON1) is an HDL-associated enzyme whose activity has consistently been associated with vascular disease (1–5). A role of PON1 in vascular disease is strongly supported by knockout and transgenic mouse studies (6, 7). The inhibition of LDL oxidation by HDL, due to metabolism of bioactive lipid hydroperoxidases, appears to be partially attributable to PON1 (8–11). Paraoxonase has been reported to reduce mildly oxidized phospholipids by eliminating these hydroperoxy derivatives of unsaturated fatty acids (9). Watson et al. (10) reported that inactivation of PON1 reduces the ability of HDL to inhibit LDL modification and also reduces the ability of HDL to inhibit monocyte-endothelial interactions, both of which may be important in the inflammatory response in artery wall cells that promotes atherogenesis. Inactivation of PON1 by oxidized LDL can be inhibited by antioxidants (12). PON1 inhibition of HDL oxidation preserves the reverse cholesterol function of HDL (13).

PON1 has four known common functional polymorphisms, two that change amino acids (PON1_Q192R, PON1_M55L), and two that alter promoter activity (PON1_–108C/T and PON1_–162A/G). Studies of the role of the coding polymorphisms in vascular disease have been contradictory (14–25). We have consistently found that the PON1_Q192R, PON1_M55L, PON1_–108C/T, and PON1_–162A/G genotypes fail to predict carotid artery disease (CAAD) in modest sample sizes, when PON1 activities are predictive of CAAD (2, 3). Meta-analyses suggest that the PON1_Q192R and PON1_M55L (and in one study, PON1_–108C/T) genotypes do not predict cardiovascular disease (CVD) (26–28). Interestingly, a study of severity of CVD did show a PON1_Q192R effect (29), and the studies for prediction of stroke or CAAD (22, 30–34) have been more consistently positive for a PON1 locus effect, although negatives occur (35) and the studies tend to be small. Of note, the polymorphisms previously studied represent only a small fraction of PON1 genetic variation: reported studies have examined only a handful of the more than 150 known PON1 region polymorphisms.

The three paraoxonase gene family members are clustered in a segment of 140 kilobase pairs on chromosome 7. The order of the three genes in the cluster is PON1, PON3, and PON2, with PON1 the most centromeric (5'). PON3 has a tissue distribution similar to that of PON1 (36), but lower expression levels, whereas PON2 is more ubiquitously expressed (37). Both PON2 and PON3 have antioxidant activity (38). The PON2_S311C coding SNP has been implicated in CVD (29, 37, 39), particularly in smokers (40). Only PON2 is expressed in human macrophages (38), where it is induced by oxidized LDL (41). However, PON1 appears to mediate macrophage cholesterol efflux (42). Given these data for PON2 and the cooccurrence of PON3 with PON1 on HDL, it is possible that PON2 and PON3 may be important in vascular disease.

PON1 is identical to the enzyme homocysteine (Hcy)-thiolactone hydrolase (43). PON1 has been suggested to protect against the atherosclerotic effects of Hcy-thiolactone (44). The reported rates of Hcy-thiolactone conversion by PON1 are very slow (reported as per hour vs. per minute for phenylacetate); thus, the PON1 metabolism of Hcy-thiolactone may not be physiologically significant. The Framingham study found that Hcy level predicted cerebrovascular, cardiovascular, and all-cause death (45, 46). It has been noted that although most cross-sectional studies support a relationship between moderate Hcy elevation and cardiovascular disease, the prospective studies are less convincing (47). However, like PON1, Hcy has more consistently been associated with cerebrovascular than with CVD (48–51). If PON1 is associated with Hcy level, this may be another possible mechanism of PON1 effects in CAAD.

Known PON1 polymorphisms do not account for all of the variability in PON1 protein level or activity. It is possible that there are other functional PON1 SNPs that could play a role in prediction of CAAD status. Use of sequencing for detection of all common polymorphisms has found previously undetected functional variability in the coding and noncoding regions of the APOE gene that predicts both APOE protein level (52) and lipid effects (53). This approach can detect most of the genetic variance in a trait that is determined at the structural locus (54). Therefore, we used sequencing and tagSNP selection to look for additional functional variability at the PON1/2/3 cluster.

The goals of this study were 3-fold. First, it has been proposed that the disconnect between PON1 activity, but not genotype, and prediction of vascular disease might be explained by unknown common functional variation in the PON1/2/3 cluster that impacts disease risk. We addressed this by extending the study of the PON1 genotype to all common variation in the PON1/2/3 cluster using a tagging single-nucleotide polymorphism (tagSNP) approach and evaluating the prediction of PON1 activity and CAAD status. Second, we compared phenotype prediction considering tagSNPs versus haplotypes to determine which method best explained the variance. Third, we explored possible mechanisms of PON1 effects in vascular disease by evaluating PON1 activity and all common PON1/2/3 cluster variance on LDL susceptibility to oxidation ex vivo and Hcy. We have previously shown that LDL susceptibility to oxidation is predictive of CAAD (55).

	METHODS

TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
Sample
The sample population included 500 Caucasian males from the previously described, ongoing CLEAR study (3, 55). Briefly, subjects were drawn from the tails of the carotid artery disease distribution. Cases (n = 205) had >80% stenosis of one or both internal carotid arteries, and controls (n = 232) had <15% stenosis bilaterally on duplex ultrasound. Additionally, controls had no known atherosclerotic vascular disease and were age-distribution-matched with the cases based on the age of onset of disease (censored age). The remaining subjects (N = 63) had intermediate internal carotid stenosis levels, between 50% and 79% unilaterally or bilaterally by ultrasound. Because of the substantial differences in allele frequency observed at PON1 between ethnicities and differences in genotype effects by gender, the study was limited to Caucasian males to avoid population stratification artifacts. Other exclusion criteria included autosomal dominant familial hypercholesterolemia or coagulopathy. Current smoking status was obtained by survey. Use of statin medications was ascertained by report and reconciled with review of pharmacy and medical records. Self-reported race was confirmed by STRUCTURE analyses with three ancestral groups (56), with excellent concordance. Height and weight were measured, with self-report used to complete missing data. The study was approved by both the University of Washington and the Veterans Affairs Puget Sound Health Care System human subject review processes. Subjects gave written informed consent.

Cases had a mean current age of 70.0 years (range 46–89 years), controls had a mean current age of 66.3 years (range 37–83 years), and the 50–79% stenosis subjects had a mean current age of 70.5 years (range 50–85 years). The rate of current smoking differed by group: 37% in cases, 14% in controls, and 26% in 50–79% stenosis subjects.

Illumina system tagSNP genotyping
TagSNPs were genotyped by Illumina on the Illumina BeadStation Laboratory System platform. Illumina technology provides a robust and accurate genotyping platform using highly multiplexed ligation assays with multiple levels of specificity to obtain optimal results (57, 58). Genotypes were called using the Illumina GenCall software package that normalizes and clusters the raw scan data. Other collaborative studies performed in the Nickerson laboratory using this system have resulted in 1,152 SNPs assayed in approximately 1,200 DNA samples with a genotyping call frequency of 99% and a reproducibility of >99%. Quality control on two PON1 SNPs typed by our lab and also by Illumina detected no Illumina errors in 1,204 genotypes. This low error rate is particularly important when looking for low-risk alleles in case-control data.

TagSNPs were selected for PON1 and PON2 from complete resequencing data from the SeattleSNPs Program for Genomic Applications (pga.gs.washington.edu), using the LDselect program. LDselect was run independently in the African American Descent (AD) and European American Descent (ED) SeattleSNPs populations. LDselect parameter thresholds of r² > 0.64 and minor allele frequencies (MAFs) greater than 5% were used for tagSNP selection in the ED population; thresholds of r² > 0.64 and MAF > 10% were used in the AD population. Because resequencing data were not yet available from the PON3 locus, a set of eight SNPs evenly distributed across the locus were selected from dbSNP for genotyping. Resequencing data are now available for PON3, and at an r² threshold of 0.64, the eight genotyped SNPs from PON3 tag 52 out of 57 SNPs with MAF > 5% in the ED population. Genotype was scored on all available subjects for 53 SNPs from the PON gene cluster (Table 1 ), with 4 functional and 26 tagSNPs in PON1, 15 tagSNPs in PON2, and 8 tagSNPs in PON3. Forty-six "common" tagSNPs were observed with MAFs greater than 5% in the studied population.

PON1 hydrolysis phenotypes
The activity of PON1 in the hydrolysis of paraoxon, diazoxon, and phenylacetate (arylesterase activity) was measured by a continuous spectrophotometric assay with lithium heparin plasma, as described elsewhere (62–65). These are termed POase, DZOase, and Arylase activities, respectively. PON1 Arylase activity showed the strongest predictive value for CAAD case control status in this cohort (P < 0.001; POase and DZOase, P > 0.05, considering square root (sqrt)-transformed activities), so we focused our efforts on predicting Arylase activity, which allows comparison across PON1_Q192R genotypes. Arylesterase activity is a good reflection of the levels of PON1 present, because the catalytic efficiency of Arylase activity is not affected by the PON1_Q192R polymorphism, allowing for comparison of PON1 levels across PON1_Q192R genotypes (66), and Arylase activity predicts vascular disease.

Oxidative measures
LDL oxidation susceptibility was measured essentially as described by Esterbauer et al. (67), as modified by Crawford et al. (68), and as validated in the prediction of CAAD (55). LDL ( = 1.019–1.063 g/ml) was isolated from plasma by density gradient ultracentrifugation. The concentration of LDL was kept constant at 100 µg/ml based on protein, and oxidation was initiated by the addition of 1.66 µM freshly prepared copper sulfate solution to the LDL, to a final concentration of 5 µM, incubated at 37°C. The kinetics of LDL oxidation were determined by the change in the absorbance at 234 nm on a Beckman DU-70 spectrometer allowing measurement of six samples simultaneously. The susceptibility to oxidation is described by 1) the lag time in minutes, defined as that interval between initiation and intercept of the tangent of the slope of the absorbance curve (lagtime); 2) the maximal rate of oxidation (LDLrate), defined as the slope of the absorbance curve during the propagation phase; and 3) the maximal change in oxidation (LDLmaxox), also determined with this assay by measuring the change of absorbance over time. These measures were available on a subset of 387 subjects. LDLrate is correlated with both lagtime and LDLmaxox, but lagtime and LDLmaxox are uncorrelated (55).

Homocysteine
Fasting plasma Hcy was measured after all forms were reduced with sodium borohydride and tris-(2-carboxyethyl) phosphine. After addition of the internal standard (cysteamine), the thiol group of homocysteine and the other thiol compounds present in the sample were derivatized with monobromobimane. The excess monobromobimane was removed by glacial acetic acid extraction. Derivatized Hcy was quantified by high-pressure liquid chromatography developed by an acetonitrile gradient. Derivatized Hcy was detected by fluorescence.

Analysis
Missing genotype data were inferred for each PON locus independently using PHASE v2.0 software (69). Regression analysis was performed in the R statistical environment (Raqua version 2.1.1, Mac OSX 10.4.2) using either the standard regression tools available within R or the haplo.glm tools from the haplo.glm package (70). Models incorporating haplotype were built using the haplo.glm package, which infers a matrix of haplotype probabilities for each individual using the expectation maximization algorithm and which estimates regression coefficients corresponding to each haplotype. To evaluate the candidate SNPs, model comparison (criticism) was performed using Akaike's Information Criterion (AIC) to evaluate the fit of each model to the observed data, starting from a base model, with age, smoking status, and genotype at the four previously described SNPs as covariates. AIC aims to identify models with good predictive characteristics, and is particularly useful in comparing models with different numbers of explanatory variables, because the criterion is based on the maximized log likelihood plus a penalty for the number of explanatory variables. Genotypes for SNPs were encoded as allele counts (0, 1, or 2) for genotype-based regressions. Statin drug use was considered as a covariate for prediction of Arylase and LDLmaxox. It was not considered as a predictor of CAAD status, due to confounding of subjects with CAAD being placed on statins at higher rates than subjects without CAAD with similar lipid profiles.

	RESULTS

TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

 
PON1 functional SNP analysis of Arylase prediction
Arylase activity showed an approximately normal distribution in the population, with an observed mean of 104.6 U/l and a standard deviation (SD) of 42.3. Previous work has identified four functional polymorphisms in the PON1 gene, PON1_Q192R, PON1_M55L, PON1_–108C/T, and PON1_–162A/G. A regression model incorporating these genotypes, smoking status, and age as predictors explained 25.9% more of the variance in Arylase activity than did a model with age and smoking but without genotype data (Table 2 ). Inclusion of statin drug use as a predictor did not significantly improve Arylase prediction. No interactions between case status and PON1 genotypes were significant at a 0.1 level in the prediction of Arylase; examination of the coefficients for cases and controls separately (Table 2) showed a high degree of similarity. Alternatively, a smoking by case status interaction was significant in the prediction of Arylase (P = 0.003); cases had a higher rate of smoking than did controls. Of those who smoked, cases smoked 1.24 packs per day (SD 0.60) on average and controls 1.19 packs per day (SD 0.54).

AIC was used to assess whether the additional polymorphisms within PON1 provided a better fit to the Arylase activity data. Starting from a base model with age, smoking status, and genotype at the four known functional SNPs as predictor variables, we ran a forward model analysis allowing the additional 26 PON1 tagSNPs to enter the model one at a time. Table 2 shows that the best-fit model incorporated an additional six SNPs into the model (SNPs in order of model entry: PON1₆₈₄₂, PON1₂₉₀₂₁, PON1₈₉₅, PON1₁₂₄₇₁, PON1₂₃₈₈₇, and PON1₁₉₄₇₀). Results from a stepwise regression model comparison, allowing explanatory variables to enter or leave the model at each step, were the same, with the exception that PON1₁₈₁₅₂ was dropped from the model. The AIC is a relatively lenient criterion for model comparison, and is expected to allow approximately 15% of null explanatory variables to enter the best-fit model. Thus, given 26 additional SNPs considered, on average four (26 x 15% = 3.9) null genotype variables would be expected to enter the model by chance, and perhaps fewer, given that correlations between tagSNPs (LD) effectively reduce the number of independent explanatory variables. Again, no PON1 genotype by case status interactions were found to be significant in the prediction of Arylase, and smoking by case status genotype was significant (P = 0.009).

We then explored the best-fit PON1 tagSNP model using haplo.glm (70). Using stepwise forward model regression, and starting from the base 4 SNP model, we allowed the six tagSNPs identified by the genotype-based stepwise analysis to enter the model. The best-fit haplotype model incorporated four of these SNPs: PON1₂₉₀₂₁, PON1₈₉₅, PON1₂₃₈₈₇, and PON1₁₉₄₇₀. Thus, it appears that some, but not all, of the additional tagSNPs in the best-fit genotype model were tagging haplotypes distinct from the four known, functional SNPs.

We further explored, by running forward stepwise regression, whether common variation at the PON2 and PON3 loci might impact Arylase activity. Starting from a model with the four functional PON1 genotypes, age, and smoking status as predictor variables, we ran a forward model analysis allowing the additional 49 tagSNPs from PON1, PON2, or PON3 to enter the model one at a time. The best-fit model, as judged by the minimum AIC, incorporated an additional seven SNPs (in order of model entry: PON1₆₈₄₂, PON1₂₉₀₂₁, PON1₈₉₅, PON1₁₂₄₇₁, PON2₄₇₁₅, PON1₂₃₈₈₇, and PON1₅₆₆₃). It is interesting to note that all but one of the tagSNPs that entered the model were within PON1, and all but one of the tagSNPs that entered the PON1-only model were also in this model (PON1₆₈₄₂, PON1₂₉₀₂₁, PON1₈₉₅, PON1₁₂₄₇₁, and PON1₂₃₈₈₇), with the PON1₁₉₄₇₀ site replaced by PON1₅₆₆₅ when PON2₄₇₁₅ was in the model. Given the number of tagSNPs considered, the entry of one PON2 and no PON3 genotypes into the model suggests little if any role for these genes in Arylase prediction.

Prediction of homocysteine and LDL ex vivo oxidation
Homocysteine levels ranged from 5.5 µmol/l to 119.9 µmol/l, with a mean of 15.44 and a roughly exponential distribution, so we explored the relationship between PON1 genotypes and log-transformed Hcy levels. Again, regression-based model comparison was used to explore this relationship. As judged by AIC, the null model with only age and smoking status as explanatory variables was the best fit model for log Hcy levels; Arylase activity did not significantly predict Hcy, and neither PON1 functional SNPs nor tagSNPs improved Hcy prediction.

Three measures of LDL oxidative susceptibility were available from the same assay of LDL (see METHODS) for 387 subjects. LDLmaxox showed the strongest predictive value for case control status within this study (55), so we assessed how well PON1 genotypes predicted LDLmaxox (Table 4 ). The initial round of analysis identified an overly influential outlier, so this data point was discarded from analysis. There was no correlation between LDLmaxox and Arylase, apolipoprotein [A-I], or lipoprotein [a] in either cases or controls (the absolute value of correlations were <0.1, all P > 0.1). Age, smoking, and statin drug use were considered as possible covariates, but only statin use was predictive. Genotypes at six PON1 loci entered the best-fit model: PON1₃₆₂₅, PON1₆₀₅₄, PON1₁₆₉₆, PON1₁₂₄₇₁, PON1₂₇₆₇₈, and PON1₂₃₈₈₇. Three of these SNPs (PON1₁₆₉₆, PON112471, and PON1₂₃₈₈₇) overlapped with the best-fit model for Arylase. Statin use was associated with a higher LDLmaxox, which is correlated with CAAD. Thus, it is likely that the statin effect was acting as a surrogate for disease status and was not indicative of the effect of the drug. Inclusion of statin use as a predictor only modestly influenced the PON1 tagSNP regression coefficients, and no significant PON1 genotype by statin use interaction effects were detected. Allowing additional tagSNPs from the PON2 and PON3 genes to enter the model added two SNPs: PON2₂₃₉₅₆ and PON3₁₃₃₅₀.

	DISCUSSION

TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

We also investigated whether other common polymorphisms in the region might explain substantially more of the Arylase activity phenotype than did the previously described functional polymorphisms. By genotyping a total of 30 tagSNPs across PON1, we now have a comprehensive collection of common variation within the gene, and regression analysis suggests that additional common polymorphisms beyond the four previously described polymorphisms probably do contribute to the Arylase phenotype. However, genotype at the four known functional polymorphisms alone explains 25.9% of residual phenotypic variance, after adjustment for age and smoking, whereas the best-fit model (with an additional six SNPs) explains 29.8% of this phenotypic variance. This difference is much more modest than the previously reported 20.4% to 33.4% variance explained by five PON1 genotypes (PON1_-909, PON1_-162, PON1_-108, PON1₅₅, and PON1₁₉₂) or haplotypes derived from those five sites (72). So although additional functional variation at PON1 exists, most cis variation has already been accounted for by the four known functional SNPs. Rare SNPs with large effects on PON1 activity are known (73), as are environmental factors that modestly influence PON1 activity, such as age and smoking (3). However, there may also be genetic variability at other loci that modulates PON1 levels. Although PON1 knockout mice have no measurable paraoxonase activity (6), this does not rule out modifier genes.

Interestingly, among the additional tagSNPs associated with Arylase activity, several SNPs that are strongly, but not perfectly, correlated with the known functional SNPs entered the model. For example, PON1₈₉₅ is in strong LD (r² = 0.72) with the promoter PON1_-108C/T SNP (PON1₁₆₉₆), suggesting that additional regulatory polymorphisms in the promoter region are likely to be relevant in predicting Arylase activity. Similarly, the PON1₁₉₄₇₀ SNP is strongly correlated with the PON1_Q192R polymorphism (r² = 0.92), and the PON1₂₉₀₂₁ SNP is strongly correlated with PON1_M55L (r² = 0.67), but in each case, the correlation is imperfect, suggesting additional functional variation within the context of the major functional polymorphisms. Finally, the PON1₂₃₈₈₇ SNP is a rare polymorphism in Europeans, but is more frequent in African Americans and is strongly associated with PON1₂₇₇₃₇ in African Americans (r² = 0.68). Polymorphisms that are frequent in African Americans may be rare in Europeans due to founder effects, drift, or negative selection. PON1₂₇₇₃₇ lies in the 3' untranslated region, making it an attractive candidate for regulatory function via RNA stability, secondary structure, or other 3' effects. The exact nature of the functional alterations associated with each tagSNP will require further exploration with in vitro studies.

Extending this analysis beyond PON1 genotypes confirmed the expectation that PON2 and PON3 polymorphisms contribute relatively little to the PON1 Arylase activity phenotype, inasmuch as all but one of the tagSNPs in the best-fit model using all variation in the region were within PON1. This is consistent with biochemical results indicating that PON2 and PON3 have negligible Arylase activity (74, 75).

Neither PON1 genotypes nor Arylase activity predicted homocysteine level. Although PON1 has been shown to have some Hcy-thiolactonase activity in previous studies, this has been argued to be at physiologically irrelevant rates due to the very low catalytic efficiency of PON1. The results of this study were consistent with this assertion.

The relationship between PON1 variation and LDLmaxox is substantially more interesting than the negative Hcy results. LDLmaxox was the LDL oxidation measure most strongly correlated with CAAD in this study. Although Arylase activity was not significantly correlated with LDLmaxox, a substantial number of PON1 SNPs appear to be related to this oxidative phenotype, including the functional PON1₁₆₉₆ promoter SNP (PON1_-108C/T). This result has been reported previously by others (76). This SNP has a strong impact on expression levels of PON1, and thereby upon PON1 mass and Arylase activity. However, as mentioned previously, Arylase activity shows no significant correlation with LDLmaxox. No active PON1 was present in the LDL oxidation assay, both because HDL is removed and because the EDTA destroys the activity of PON1, a calcium-dependent enzyme. Thus, PON1 effects on the oxidation assay would depend on the underlying LDL oxidative status at the time of sampling.

The effects of PON1 on LDL oxidation are controversial (74, 75, 77–79). Newer studies have questioned whether the antioxidant effects of PON1 ex vivo shown in prior work might be, in part, due to cross contamination (74, 77). However, work on recombinant PON1, which is not susceptible to similar purification issues, confirmed that PON1 did influence oxidized LDL levels as measured by the oxidized LDL-stimulated MCP-1 secretion, whereas HDL without PON1 did not (78). Another study of recombinant PON1, PON2, and PON3 without HDL present did not find that any had an effect on ex vivo oxidative susceptibility of LDL, considering the lag time phenotype (75), which is uncorrelated with LDLmaxox and a weaker predictor of CAAD in our cohort (55). HDL from PON1 knockout mice does not protect LDL from oxidation (80), and PON1 transgenic mice have improved protection of LDL from oxidation (81).

If PON1 genotype predicts LDL oxidative susceptibility, this strongly suggests a PON1 role. It is not yet clear how PON1 genotypes are related to LDLmaxox when Arylase is not. One possibility is that the PON1 activity for Arylase does not reflect the PON1 activity for the LDLmaxox relevant substrate. This is consistent with the finding that site-specific mutagenesis of PON1_284CYS decreases PON1 antioxidant activity, but not its Arylase activity (82). We did not detect PON1₁₉₂ effects on LDLmaxox; prior studies of this polymorphism for the phenotype lag time have been mixed (76, 83). A PON1_-108 effect on both lag time and LDL oxidation rate has been reported (76).

Extending our analysis from intermediate phenotypes to the clinical phenotype of CAAD, our previous analyses (3) showed that although PON1 functional SNP genotypes predict a significant portion of Arylase activity, and Arylase activity predicts disease status, PON1 functional SNPs are not significantly correlated with disease status. This finding is robust to analysis of additional tagSNPs in the gene, suggesting that PON1 tagSNPs are an inadequate proxy for Arylase activity in CAAD prediction. Why common PON1 genotypes that are correlated with the CVD risk factors Arylase and LDLmaxox, particularly PON1_-108, do not predict CVD remains unclear. This may be related to the observation in this study that cis variation in the PON gene cluster accounts for less than one-third of the overall variance in PON1 activity levels. Genetic variation at other loci may influence PON1 activity, or rare variation may be important, as suggested for the rare SNP PON1₂₃₈₈₇, which was found to predict Arylase, LDLmaxox, and, marginally, case status. Larger studies will be required to determine whether that is a spurious result.

In conclusion, our analysis of genetic variation at the PON1 gene revealed several important results. First, haplotype-based analysis afforded a modest advantage over genotype-based models of the Arylase activity quantitative trait, but the same panel of tagSNPs were identified as important in either analysis. Second, comprehensive tagSNP analysis of the PON1 gene suggested that additional functional polymorphisms exist, in addition to the known four functional polymorphisms, but that the majority of the cis effects are attributable to the known functional variants. Because the additional SNPs do not appear to be coding SNPs, they may include polymorphisms that affect regulation or splicing efficiency. Third, neither PON1 Arylase activity nor PON1 genotype predicted plasma Hcy levels. Additionally, although Arylase activity failed to predict the LDL ex vivo oxidation measure LDLmaxox, a number of PON1 genotypes were correlated with this variable. Taken together with the observed correlation between LDLmaxox and CAAD, this suggests that it may be regulatory variation, and not coding region variation of the PON1 on HDL particles, that is important in preventing oxidative damage, consistent with our earlier studies (3). Thus, although PON1 genotype accounts for some variability in the CAAD risk factors Arylase and LDLmaxox, capturing common genetic variation comprehensively at the PON1 structural locus is not an adequate substitute for measuring Arylase activity in the prediction of CAAD.

	ACKNOWLEDGMENTS

 
This work was funded by National Institutes of Health Grant R01 HL-67406 and the Veterans Affairs Epidemiology Research and Information Center Program (award CSP 701S), with subject identification support from National Institutes of Health Grant P01 HL-072262. TagSNP selection relied on public resequencing data from the SeattleSNPs program, supported by National Institutes of Health Grant U01 HL-66682. The authors would like to thank the subjects for their participation, and thank the following people for their technical assistance: Karen Nakayama, Jeff Rodenbaugh, Dawn Lum, Sara Spencer, Claire McClung, Erin Booker, James Berry, Sandra Steiner, and Sofia Kirova.

Manuscript received November 29, 2005 and in revised form January 17, 2006.

	REFERENCES

TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES

1. Ayub, A., M. I. Mackness, S. Arrol, B. Mackness, J. Patel, and P. N. Durrington. 1999. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 19: 330–335.[Abstract/Free Full Text]

2. Jarvik, G. P., L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 20: 2441–2447.[Abstract/Free Full Text]

3. Jarvik, G. P., T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. 2003a. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23: 1465–1471.[Abstract/Free Full Text]

4. Mackness, B., P. N. Durrington, B. Abuashia, A. J. Boulton, and M. I. Mackness. 2000. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci. (Lond.). 98: 355–363.[Medline]

5. Mackness, M. I., B. Mackness, and P. N. Durrington. 2002. Paraoxonase and coronary heart disease. Atheroscler. 3 (Suppl.): 49–55.

6. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284–287.[CrossRef][Medline]

7. Tward, A., Y. R. Xia, X. P. Wang, Y. S. Shi, C. Park, L. W. Castellani, A. J. Lusis, and D. M. Shih. 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 106: 484–490.[CrossRef][Medline]

8. Mackness, M. I., S. Arrol, C. Abbott, and P. N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104: 129–135.[CrossRef][Medline]

9. Mackness, M. I., D. Bhatnagar, P. N. Durrington, H. Prais, B. Haynes, J. Morgan, and L. Borthwick. 1994. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur. J. Clin. Nutr. 48: 859–865.[Medline]

10. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882–2891.[Medline]

11. Graham, A., D. G. Hassall, S. Rafique, and J. S. Owen. 1997. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis. 135: 193–204.[CrossRef][Medline]

12. Aviram, M., M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C. L. Bisgaier, R. S. Newton, and B. La Du. 1999. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26: 892–904.[CrossRef][Medline]

13. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581–1590.[Medline]

14. Ruiz, J., H. Blanche, R. W. James, M. C. Garin, C. Vaisse, G. Charpentier, N. Cohen, A. Morabia, P. Passa, and P. Froguel. 1995. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346: 869–872.[CrossRef][Medline]

15. Serrato, M., and A. J. Marian. 1995. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96: 3005–3008.[Medline]

16. Pfohl, M., M. Koch, M. D. Enderle, R. Kuhn, J. Fullhase, K. R. Karsch, and H. U. Haring. 1999. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 48: 623–627.[Abstract]

17. Heijmans, B., R. G. Westendorp, A. M. Lagaay, D. L. Knook, C. Kluft, and P. E. Slagboom. 2000. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis. 149: 91–97.[CrossRef][Medline]

18. Antikainen, M., S. Murtomaki, M. Syvanne, R. Pahlman, E. Tahvanainen, M. Jauhiainen, M. H. Frick, and C. Ehnholm. 1996. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98: 833–835.

19. Rice, G. I., N. Ossei-Gerning, M. H. Stickland, and P. J. Grant. 1997. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron. Artery Dis. 8: 677–682.[Medline]

20. Herrmann, S. M., H. Blanc, O. Poirier, D. Arveiler, G. Luc, A. Evans, P. Marques-Vidal, J. M. Bard, and F. Cambien. 1996. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 126: 299–303.[CrossRef][Medline]

21. Suehiro, T., Y. Nakauchi, M. Yamamoto, K. Arii, H. Itoh, N. Hamashige, and K. Hashimoto. 1996. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 57: 69–73.[CrossRef][Medline]

22. Schmidt, H., R. Schmidt, K. Niederkorn, A. Gradert, M. Schumacher, N. Watzinger, H. P. Hartung, and G. M. Kostner. 1998. Paraoxonase PON1 polymorphism leu-met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke. 29: 2043–2048.[Abstract/Free Full Text]

23. Sanghera, D. K., N. Saha, C. E. Aston, and M. I. Kamboh. 1997. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17: 1067–1073.[Abstract/Free Full Text]

24. Cascorbi, I., M. Laule, P. M. Mrozikiewicz, A. Mrozikiewicz, C. Andel, G. Baumann, I. Roots, and K. Stangl. 1999. Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics. 9: 755–761.[Medline]

25. Sanghera, D. K., N. Saha, and M. I. Kamboh. 1998b. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 136: 217–223.[CrossRef][Medline]

26. Lawlor, D. A., I. N. Day, T. R. Gaunt, L. J. Hinks, P. J. Briggs, M. Kiessling, N. Timpson, G. D. Smith, and S. Ebrahim. 2004. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet. 5: 17.[CrossRef][Medline]

27. Wheeler, J. G., B. D. Keavney, H. Watkins, R. Collins, and J. Danesh. 2004. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 363: 689–695.[CrossRef][Medline]

28. Lohmueller, K. E., C. L. Pearce, M. Pike, E. S. Lander, and J. N. Hirschhorn. 2003. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33: 177–182.[CrossRef][Medline]

29. Chen, Q., S. E. Reis, C. M. Kammerer, D. M. McNamara, R. Holubkov, B. L. Sharaf, G. Sopko, D. F. Pauly, C. N. Merz, and M. I. Kamboh. 2003. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am. J. Hum. Genet. 72: 13–22.[CrossRef][Medline]

30. Voetsch, B., K. S. Benke, B. P. Damasceno, L. H. Siqueira, and J. Loscalzo. 2002. Paraoxonase 192 GlnArg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke. 33: 1459–1464.[Abstract/Free Full Text]

31. Voetsch, B., K. S. Benke, C. I. Panhuysen, B. P. Damasceno, and J. Loscalzo. 2004. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. Arch. Neurol. 61: 351–356.[Abstract/Free Full Text]

32. Ueno, T., E. Shimazaki, T. Matsumoto, H. Watanabe, A. Tsunemi, Y. Takahashi, M. Mori, R. Hamano, T. Fujioka, M. Soma, et al. 2003. Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population. Med. Sci. Monit. 9: CR208–CR212.[Medline]

33. Schmidt, R., H. Schmidt, F. Fazekas, P. Kapeller, G. Roob, A. Lechner, G. M. Kostner, and H. P. Hartung. 2000. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the austrian stroke prevention study. Arterioscler. Thromb. Vasc. Biol. 20: 1811–1816.[Abstract/Free Full Text]

34. Markus, H., Z. Kapozsta, R. Ditrich, C. Wolfe, N. Ali, J. Powell, M. Mendell, and M. Cullinane. 2001. Increased common carotid intima-media thickness in UK African Caribbeans and its relation to chronic inflammation and vascular candidate gene polymorphisms. Stroke. 32: 2465–2471.[Abstract/Free Full Text]

35. Topic, E., A. M. Timundic, M. Ttefanovic, V. Demarin, V. Vukovic, A. Lovrencic-Huzjan, and I. Zuntar. 2001. Polymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. Clin. Chem. Lab. Med. 39: 346–350.[CrossRef][Medline]

36. Reddy, S. T., D. J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D. M. Shih, A. J. Lusis, M. Navab, and A. M. Fogelman. 2001. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol. 21: 542–547.[Abstract/Free Full Text]

37. Ng, C. J., D. J. Wadleigh, A. Gangopadhyay, S. Hama, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2001. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276: 44444–44449.[Abstract/Free Full Text]

38. Rosenblat, M., D. Draganov, C. E. Watson, C. L. Bisgaier, B. N. La Du, and M. Aviram. 2003. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23: 468–474.[Abstract/Free Full Text]

39. Pan, J. P., S. T. Lai, S. C. Chiang, S. C. Chou, and A. N. Chiang. 2002. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei). 65: 415–421.

40. Martinelli, N., D. Girelli, O. Olivieri, C. Stranieri, E. Trabetti, F. Pizzolo, S. Friso, I. Tenuti, S. Cheng, M. A. Grow, et al. 2004. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur. J. Clin. Invest. 34: 14–20.[CrossRef][Medline]

41. Rosenblat, M., T. Hayek, K. Hussein, and M. Aviram. 2004. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler. Thromb. Vasc. Biol. 24: 175–180.[Abstract/Free Full Text]

42. Rosenblat, M., J. Vaya, D. Shih, and M. Aviram. 2005. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis. 179: 69–77.[CrossRef][Medline]

43. Jakubowski, H. 2000. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275: 3957–3962.[Abstract/Free Full Text]

44. Jakubowski, H. 1999. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 13: 2277–2283.[Abstract/Free Full Text]

45. Selhub, J., P. F. Jacques, A. G. Bostom, R. B. D'Agostino, P. W. Wilson, A. J. Belanger, D. H. O'Leary, P. A. Wolf, E. J. Schaefer, and I. H. Rosenberg. 1995. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 332: 286–291.[Abstract/Free Full Text]

46. Bostom, A. G., and J. D. Easton. 1992. Serum lipoprotein (a) as a risk factor for extracranial carotid artery atherosclerosis [letter] [see comments]. Mayo Clin. Proc. 67: 303–304.[Medline]

47. Christen, W. G., U. A. Ajani, R. J. Glynn, and C. H. Hennekens. 2000. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch. Intern. Med. 160: 422–434.[Abstract/Free Full Text]

48. Clarke, R., L. Daly, K. Robinson, E. Naughten, S. Cahalane, B. Fowler, and I. Graham. 1991. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324: 1149–1155.[Abstract]

49. Boers, G. H., A. G. Smals, F. J. Trijbels, B. Fowler, J. A. Bakkeren, H. C. Schoonderwaldt, W. J. Kleijer, and P. W. Kloppenborg. 1985. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N. Engl. J. Med. 313: 709–715.[Abstract]

50. Perry, I. J., H. Refsum, R. W. Morris, S. B. Ebrahim, P. M. Ueland, and A. G. Shaper. 1995. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346: 1395–1398.[CrossRef][Medline]

51. Dudman, N. P., D. E. Wilcken, J. Wang, J. F. Lynch, D. Macey, and P. Lundberg. 1994. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler. Thromb. Vasc. Biol. 13: 1253–1260.

52. Hamon, S. C., J. H. Stengard, A. G. Clark, V. Salomaa, E. Boerwinkle, and C. F. Sing. 2004. Evidence for non-additive influence of single nucleotide polymorphisms within the apolipoprotein E gene. Ann. Hum. Genet. 68: 521–535.[CrossRef][Medline]

53. Stengard, J. H., A. G. Clark, K. M. Weiss, S. Kardia, D. A. Nickerson, V. Salomaa, C. Ehnholm, E. Boerwinkle, and C. F. Sing. 2002. Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism. Am. J. Hum. Genet. 71: 501–517.[CrossRef][Medline]

54. Wootton, P. T., F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud. 2005. Tagging SNP haplotype analysis of the secretory PLA2-IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Hum. Mol. Genet. 15: 355–361.

55. Hendrickson, A., L. A. McKinstry, J. K. Lewis, J. Lum, A. Louie, G. D. Schellenberg, T. S. Hatsukami, A. Chait, and G. P. Jarvik. 2005. Ex vivo measures of LDL oxidative susceptibility predict carotid artery disease. Atherosclerosis. 179: 147–153.[CrossRef][Medline]

56. Pritchard, J. K., M. Stephens, and P. Donnelly. 2000. Inference of population structure using multilocus genotype data. Genetics. 155: 945–959.[Abstract/Free Full Text]

57. Fan, J. B., A. Oliphant, R. Shen, B. G. Kermani, F. Garcia, K. L. Gunderson, M. Hansen, F. Steemers, S. L. Butler, P. Deloukas, et al. 2003. Highly parallel SNP genotyping. Cold Spring Harb. Symp. Quant. Biol. 68: 69–78.[CrossRef][Medline]

58. Oliphant, A., D. L. Barker, J. R. Stuelpnagel, and M. S. Chee. 2002. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques. 56–58 (Suppl.): 60–61.

59. Miller, S. A., D. D. Dykes, and H. F. Polesky. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.[Free Full Text]

60. Humbert, R., D. A. Adler, C. M. Disteche, C. Hassett, C. J. Omiecinski, and C. E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3: 73–76.[CrossRef][Medline]

61. Brophy, V. H., M. D. Hastings, J. B. Clendenning, R. Richter, G. P. Jarvik, and C. E. Furlong. 2001a. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics. 11: 77–84.[CrossRef][Medline]

62. Brophy, V. H., R. L. Jampsa, J. B. Clendenning, L. A. McKinstry, G. P. Jarvik, and C. E. Furlong. 2001b. Promoter polymorphism effects on paraoxonase (PON1) expression. Am. J. Hum. Genet. 68: 1428–1436.[CrossRef][Medline]

63. Furlong, C. E., R. J. Richter, S. L. Seidel, L. G. Costa, and A. G. Motulsky. 1989. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyifos and parathion by plasma paraoxonase/arylesterase. Anal. Biochem. 180: 242–247.[CrossRef][Medline]

64. Davies, H., R. J. Richter, M. Keifer, C. Broomfield, J. Sowalla, and C. E. Furlong. 1996. The effect of human serum paraoxonase polymorphism is reversed with diazoxon, soman, and sarin. Nat. Genet. 14: 334–336.[CrossRef][Medline]

65. Richter, R. J., and C. E. Furlong. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics. 9: 745–753.[Medline]

66. Furlong, C. E., N. Holland, R. J. Richter, A. Bradman, A. Ho, and B. Eskenazi. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genomics. 16: 183–190.[Medline]

67. Esterbauer, H., G. Striegl, H. Puhl, and M. Rotheneder. 1989. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic. Res. Commun. 6: 67–75.[Medline]

68. Crawford, R. S., E. A. Kirk, M. E. Rosenfeld, R. C. LeBoeuf, and A. Chait. 1998. Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18: 1506–1513.[Abstract/Free Full Text]

69. Stephens, M., N. J. Smith, and P. Donnelly. 2001. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978–989.[CrossRef][Medline]

70. Lake, S. L., H. Lyon, K. Tantisira, E. K. Silverman, S. T. Weiss, N. M. Laird, and D. J. Schaid. 2003. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum. Hered. 55: 56–65.[CrossRef][Medline]

71. Carlson, C. S., M. A. Eberle, M. J. Rieder, Q. Yi, L. Kruglyak, and D. A. Nickerson. 2004. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74: 106–120.[CrossRef][Medline]

72. Chen, J., W. Chan, S. Wallenstein, G. Berkowitz, and J. G. Wetmur. 2005. Haplotype-phenotype relationships of paraoxonase-1. Cancer Epidemiol. Biomarkers Prev. 14: 731–734.[Abstract/Free Full Text]

73. Jarvik, G. P., R. Jampsa, R. J. Richter, C. S. Carlson, M. J. Rieder, D. A. Nickerson, and C. E. Furlong. 2003b. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics. 13: 291–295.[CrossRef][Medline]

74. Teiber, J. F., D. I. Draganov, and B. N. La Du. 2004. Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J. Lipid Res. 45: 2260–2268.[Abstract/Free Full Text]

75. Draganov, D. I., J. F. Teiber, A. Speelman, Y. Osawa, R. Sunahara, and B. N. La Du. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46: 1239–1247.[Abstract/Free Full Text]

76. Sardo, M. A., S. Campo, M. Bonaiuto, A. Bonaiuto, C. Saitta, G. Trimarchi, M. Castaldo, A. Bitto, M. Cinquegrani, and A. Saitta. 2005. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr. Med. Res. Opin. 21: 777–784.[CrossRef][Medline]

77. Marathe, G. K., G. A. Zimmerman, and T. M. McIntyre. 2003. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 278: 3937–3947.[Abstract/Free Full Text]

78. Mackness, B., D. Hine, Y. Liu, M. Mastorikou, and M. Mackness. 2004. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318: 680–683.[CrossRef][Medline]

79. Connelly, P. W., D. Draganov, and G. F. Maguire. 2005. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic. Biol. Med. 38: 164–174.[CrossRef][Medline]

80. Shih, D. M., Y. R. Xia, X. P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275: 17527–17535.[Abstract/Free Full Text]

81. Oda, M. N., J. K. Bielicki, T. T. Ho, T. Berger, E. M. Rubin, and T. M. Forte. 2002. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem. Biophys. Res. Commun. 290: 921–927.[CrossRef][Medline]

82. Aviram, M., S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlop, and B. La Du. 1998a. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18: 1617–1624.[Abstract/Free Full Text]

83. Bub, A., S. W. Barth, B. Watzl, K. Briviba, and G. Rechkemmer. 2005. Paraoxonase 1 Q192R (PON1–192) polymorphism is associated with reduced lipid peroxidation in healthy young men on a low-carotenoid diet supplemented with tomato juice. Br. J. Nutr. 93: 291–297.[CrossRef][Medline]

This article has been cited by other articles:

				P. W. Connelly, G. F. Maguire, C. M. Picardo, J. F. Teiber, and D. Draganov Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma J. Lipid Res., January 1, 2008; 49(1): 245 - 250. [Abstract] [Full Text] [PDF]

<